Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Advanced Colorectal Cancer: early-phase trial registry

5 of 9 indexed Advanced Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Advanced Colorectal Cancer: 9 US clinical trials tracked, 5 recruiting.

Advanced Colorectal Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie (prior sponsor, Abbott), running 1 of these trials.

Enrollment posture brief

Registry condition advanced-colorectal-cancer

OPEN 5 | RECR 56% | LATE 1 | EARLY 8 | RANK #1916 | SPON 1

Nearest open-share peer: Agitation (56% recruiting · 9 trials)

Advanced Colorectal Canc (th…56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Advanced Colorectal Cancer

Advanced Colorectal Cancer lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Colorectal Cancer is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Advanced Colorectal Cancer trials is spread across many organizations.

    AbbVie (prior sponsor, Abbott) accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Advanced Colorectal Cancer enrolment sits around 80 participants.

    Median target enrolment is 80 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Advanced Colorectal Cancer research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 24Phase 31

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1 514 participants

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

BeiGene

NCT06585488

RECRUITING Phase 2 150 participants

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Riboscience

NCT06824064

RECRUITING Phase 1 80 participants

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Cartography Biosciences

NCT07321106

RECRUITING Phase 2 33 participants

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

NCT06369259

RECRUITING Phase 1 27 participants

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

University of Alabama at Birmingham

NCT06867822

ACTIVE NOT RECRUITING Phase 3 461 participants

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Mirati Therapeutics

NCT04793958

COMPLETED Phase 2 159 participants

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

AbbVie (prior sponsor, Abbott)

NCT00707889

COMPLETED Phase 1 23 participants

Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors

UNC Lineberger Comprehensive Cancer Center

NCT01859858

COMPLETED Phase 2 16 participants

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT02227667

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Advanced Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
2 trials
ABT-869 Drug
1 trials
mFOLFOX6 Regimen Drug
1 trials
MEDI4736 Drug
1 trials
folinic acid Drug
1 trials
MRTX849 Drug
1 trials
FOLFIRI Regimen Drug
1 trials
fluorouracil Drug
1 trials

US sites by state

Facility locations filed on Advanced Colorectal Cancer trials. A trial with sites in several states counts in each.

Texas 4 trials
California 3 trials
North Carolina 2 trials
Alabama 2 trials
Virginia 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Colorectal Cancer page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Colorectal Cancer condition card totals 9 registered trials; most-linked intervention Cetuximab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.